Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions

Bibliography

• Lekamwasam S, Adachi JD, Agnusdei D, A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012;23:2257-76
   PubMed Web of Science ®Google Scholar
• Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011;365:62-70
   PubMed Web of Science ®Google Scholar
• Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long terrm steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002;61:32-6
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 2005;365:801-3
   PubMed Web of Science ®Google Scholar
• den Uyl D, Bultink IEM, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 2011;13:233-40
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Boers M, Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69:1913-19
   PubMed Web of Science ®Google Scholar
• Canalis E, Mazziotti G, Giustina A, Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319-28
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19:893-9
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87
   PubMed Web of Science ®Google Scholar
• Natsui K, Tanaka K, Suda M, High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 2006;17:105-8
   PubMed Web of Science ®Google Scholar
• Adachi JD, Saag KG, Delmas PD, Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11
   PubMed Web of Science ®Google Scholar
• Cohen S, Levy RM, Keller M, Risedronate therapy prevents corticosteroid-induced bone loss: a twelve month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18
   PubMed Web of Science ®Google Scholar
• Reid DM, Devogelaer JP, Saag K, Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253-63
   PubMed Web of Science ®Google Scholar
• Schett G, Stach C, Zwerina J, How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum 2008;58:2936-48
   PubMed Web of Science ®Google Scholar
• Schett G, Saag KG, Bijlsma JW. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis 2010;69:1415-19
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Uhlig T, Falch JA, Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000;43:522-30
   PubMed Web of Science ®Google Scholar
• Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995;54:49-52
   PubMedGoogle Scholar
• van Staa TP, Leufkens HG, Abenhaim L, Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000
   PubMed Web of Science ®Google Scholar
• van Staa TP, Geuzens P, Pols HA, A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005;98:191-8
   PubMed Web of Science ®Google Scholar
• de Vries F, Bracke M, Leufkens HG, Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007;56:208-14
   PubMed Web of Science ®Google Scholar
• Kanis JA, Borgstrom F, de Laet C, Assessment of fracture risk. Osteoporosis Int 2005;16:581-9
   PubMed Web of Science ®Google Scholar
• Lems WF. Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum 2007;56:3518-22
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Abenhaim L, Use of oral corticosteroids in the United Kingdom. QJM 2000;93:105-11
   PubMed Web of Science ®Google Scholar
• van Staa TP, Laan RF, Barton IP, Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-9
   PubMed Web of Science ®Google Scholar
• Compston J. Clinical question: what is the best approach to managing glucocorticoid-induced osteoporosis? Clin Endocrinol (Oxf) 2011;74:547-50
   Google Scholar
• McKay LI, Cidlowski JA. Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol Endocrinol 1998;12:45-56
   PubMed Web of Science ®Google Scholar
• Vayssaire BM, Dupont S, Choquart A, Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiiflammatory activity in vivo. Mol Endocrinol 1997;11:1245-55
   Google Scholar
• Buttgereit F, Straub RH, Wehling M, Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408-17
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jilka RL, Parfitt AM, Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-82
   PubMed Web of Science ®Google Scholar
• O'Brien CA, Jia D, Plotkin LI, Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004;145:1835-41
   PubMed Web of Science ®Google Scholar
• Liu Y, Porta A, Peng X, Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k. J Bone Miner Res 2004;19:479-90
   PubMed Web of Science ®Google Scholar
• Yun SI, Yoon HY, Jeong SY, Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. J Bone Miner Metab 2009;27:140-8
   PubMed Web of Science ®Google Scholar
• Ohnaka K, Tanabe M, Kawate H, Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 2005;329:177-81
   PubMed Web of Science ®Google Scholar
• Wang FS, Ko JY, Yeh DW, Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 2008;149:1793-801
   PubMed Web of Science ®Google Scholar
• Butler JS, Queally JM, Devitt BM, Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation. BMC Musculoskelet Disord 2010;11:210
   Google Scholar
• Pereira RC, Delany AM, Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 2002;30:685-91
   PubMed Web of Science ®Google Scholar
• Shi XM, Blair HC, Yang X, Tandem repeat of C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipocyte differentiation. J Cell Biochem 2000;76:518-27
   PubMed Web of Science ®Google Scholar
• Caramo-Orive I, Gaztelumendi A, Delgado J, Regulation of human bone marrow stromal cell proliferation and differentiation capacity by glucocorticoid receptor and AP-1 crosstalk. J Bone Miner Res 2010;25:2115-25
   Google Scholar
• Hofbauer LC, Gori F, Riggs BL, Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999;140:4382-9
   PubMed Web of Science ®Google Scholar
• Kondo T, Kitazawa R, Yamaguchi A, Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem 2008;103:335-45
   PubMed Web of Science ®Google Scholar
• Kim HJ, Zhao H, Kitaura H, Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006;116:2152-60
   PubMed Web of Science ®Google Scholar
• Gillespie LD, Robertson MC, Gillespie WJ, Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009(2):CD007146
   PubMed Web of Science ®Google Scholar
• Reginster JY, Kuntz D, Verdickt W, Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporosis Int 1999;9:75-81
   PubMed Web of Science ®Google Scholar
• Amin S, LaValley MP, Simms RW, The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 1999;42:1740-51
   PubMed Web of Science ®Google Scholar
• Homik J, Suarez-Almazor ME, Shea B, Calcium and vitamin D for corticosteroid- induced osteoporosis. Cochrane Database Syst Rev 2000(2):CD000952
   Google Scholar
• Lips P. Relative value of 25(OH)D and 1,25(OH)2D measurements. J Bone Miner Res 2007;22:1668-71
   PubMed Web of Science ®Google Scholar
• Tang BM, Eslick GD, Nowson C, Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370:657-66
   PubMed Web of Science ®Google Scholar
• Kanis JA, Burlet N, Cooper C, European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428
   PubMed Web of Science ®Google Scholar
• Amin S, Lavalley MP, Simms RW, The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002;17:1512-26
   PubMed Web of Science ®Google Scholar
• Reid DM, Hughes RA, Laan RF, Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000;15:1006-13
   PubMed Web of Science ®Google Scholar
• Saag KG, Emkey R, Schnitzer TJ, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-9
   PubMed Web of Science ®Google Scholar
• Stoch SA, Saag KG, Greenwald M, Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 2009;36:1705-14
   PubMed Web of Science ®Google Scholar
• Wallach S, Cohen S, Reid DM, Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85
   PubMed Web of Science ®Google Scholar
• Hakala M, Kroger H, Valleala H, Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double- blind, placebo-controlled trial. Scand J Rheumatol 2012;41:260-6
   PubMed Web of Science ®Google Scholar
• Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 2009;24:1335-44
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J, Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Ebeling PR, Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94
   PubMed Web of Science ®Google Scholar
• Dell RM, Adams AL, Greene DF, Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012;27:2544-50
   PubMed Web of Science ®Google Scholar
• Patlas N, Golomb G, Yaffe P, Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999;60:68-73
   PubMedGoogle Scholar
• Saag KG, Shane E, Boonen S, Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39
   PubMed Web of Science ®Google Scholar
• Saag KG, Zanchetta JR, Devogelaer JP, Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009;60:3346-55
   PubMed Web of Science ®Google Scholar
• Karras D, Stoykov I, Lems WF, Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study. J Rheumatol 2012;39:600-9
   PubMed Web of Science ®Google Scholar
• Dore RK, Cohen SB, Lane NE, Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010;69:872-5
   PubMed Web of Science ®Google Scholar
• Kanis JA, Stevenson M, McCloskey EV, Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2007;11:1-256
   Web of Science ®Google Scholar
• Buckley LM, Hillner BE. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. J Rheumatol 2003;30:132-8
   Google Scholar
• Beukelman T, Saag KG, Curtis JR, Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. Osteoporosis Int 2010;21:1573-84
   Google Scholar
• Van Staa TP, Geusens P, Zhang B, Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatology 2007;46:460-6
   Google Scholar
• Grossman JM, Gordon R, Ranganath VK, American college of rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515-26
   PubMed Web of Science ®Google Scholar
• DVO Guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Available from: www.dv-osteologie.org/dvo_leitlinien/dvo-leitlinie-2009
   Google Scholar
• Silverman S, Gold DT. Compliance and persistence with osteoporosis medications: a critical review of the literature. Rev Endocr Metab Disord 2010;11:275-80
   PubMed Web of Science ®Google Scholar
• Netelenbos JC, Geusens PP, Ypma G, Adherence and profile of non-persistence in patients treated for osteoporosis – a large scale, long-term retrospective study in The Netherlands. Osteoporos Int 2011;22:1537-46
   PubMed Web of Science ®Google Scholar
• Ziller V, Kostev K, Kyvernitakis I, Persistence and compliance of medications used in the treatment ofosteoporosis- -analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 2012;50:315-22
   PubMed Web of Science ®Google Scholar
• Silverman SL, Schousboe JT, Gold DT. Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 2011;22:21-6
   PubMed Web of Science ®Google Scholar
• de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Preferences of GPs and patients for peventive osteoporosis drug treatment: a discrete-choice experiment. Pharmacoeconomics 2009;27:211-19
   Google Scholar
• Newman ED, Matzko CK, Olenginski TP, Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 2006;17:1428-34
   PubMed Web of Science ®Google Scholar
• Bultink IE, Vis M, van der Horst-bruinsma IE, Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep 2012;14:224-30
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Sambrook PN. Anabolic therapy in glucocortcoid-induced osteoporosis. N Engl J Med 2007;357:2084-6
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum 2011;63:325-8
   PubMedGoogle Scholar
• National osteoporosis foundation's clinician's guide to the prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC; 2009
   Google Scholar
• Bone and tooth society of Great Britain. Guidelines on the prevention and treatment of glucocorticoid-induced osteoporosis. Royal College of Physicians, London; 2003
   Google Scholar
• Devogelaer JP, Goemaere S, Boonen S, Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006;17:8-19
   PubMed Web of Science ®Google Scholar
• Dutch CBO guideline osteoporosis and fracture prevention. 2011. Available from: www.cbo.nl/en/Guidelines
   Google Scholar
• Finnish national guidelines for treatment of osteoporosis. 2006. Available from: www.kaypahoito.fi/web/english/guidelines
   Google Scholar